In conclusion, emerging data suggest that the combination of SGLT2 and RAAS inhibitors appear to have similar cardiovascular and renal benefits in patients with type 2 diabetes compared with SGLT2 inhibitors alone. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.